30
Borrow years of expertise
Borrow 30 years of expertise
Team up with our scientists for the easier route to breakthroughs
Experience the safety of expert guidance in early-stage drug development
Backed by precision-driven assay technologies
Here’s how we help you go from cells to success
Streamlining your discovery journey
Understanding disease mechanisms
Preclinical mastery for safer outcomes
Here’s how we help you go from cells to success
Streamlining your discovery journey
Understanding disease mechanisms
Reveal deeper pathology with our EHTs for detailed functional profiling, from toxicity studies to gene therapy.
EHTs, created from human induced pluripotent stem cells, are 3D cardiac constructs that accelerate preclinical research and enhance personalized medicine studies.
Preclinical mastery for safer outcomes
Our Technology
Shaping your pulse of progress with EHT technology
Engineered Heart Tissues (EHTs¹) are three-dimensional, fibrin-based cardiac constructs derived from human induced pluripotent stem cells (hiPSCs). Our innovative technology combines hiPSCs with 3D tissue engineering to simulate human heart tissues, enabling precise cardiac safety and efficacy testing, disease modeling and precision medicine including gene therapy applications.
EHTs not only facilitate the rapid translation of research findings into preclinics but also provide a powerful testbed for personalized medicine approaches.
EHTs, created from human induced pluripotent stem cells, are 3D cardiac constructs that accelerate preclinical research and enhance personalized medicine studies.
Our Process
How to work with us
01
Talk to experts
02
Customized planning
03
Expert execution
04
Tangible outcomes
Your ally in early-stage pharmaceutical endeavors
For pharma companies
For biotechs
For academia
FAQs
How do DiNABIOS' services facilitate comprehensive drug discovery and toxicity screening?
Utilizing the EHT technology and the DiNAQUBE™ platform, we offer a range of services including cardiomyocyte differentiation, contractility assays, disease modeling, and cardiotoxicity screening. Our approach streamlines your drug discovery process, providing crucial insights into cardiac safety and efficacy.
Can DiNABIOS assist with customized assays for cardiac studies?
Yes, our expertise extends to customized assays, tailored for your specific cardiac research needs. This allows for more precise and relevant data in your drug development journey.
How can DiNABIOS support your research in disease modeling and efficacy studies?
DiNABIOS’ EHT technology is specialized for disease modeling, offering in-depth efficacy studies and functional assessments. Our services are ideal for modeling disease-, mutation-, and ethnic-specific responses, enhancing your therapeutic development.
Does DiNABIOS offer tailored solutions for specific research challenges?
Certainly. We provide prototyping of custom asset designs and development of bespoke software solutions to streamline your screening platforms, ensuring that your research is as effective and efficient as possible.
How does DiNABIOS contribute to academic research in cardiac sciences?
Our services, including mapping and designing preclinical studies with human induced pluripotent stem cell-derived cardiomyocytes, provide a solid foundation for fundamental cardiac research. We empower academia with tools for a deeper understanding of cardiac functions and disorders.
Can DiNABIOS support academic projects with custom-designed studies?
Yes, our team can assist in customizing studies for specific academic research objectives, leveraging our EHT technology and DiNAQUBE™ platform for precise data collection and analysis in cardiac science.
Expand your research team for smoother breakthroughs
Your data with DiNABIOS is as secure as DNA in a double helix. Check out our Privacy Policy for the specifics.